Table 2 Ongoing lifestyle randomised control trials (RCT) in cancer patients.
From: Targeting obesity-related dysfunction in hormonally driven cancers
Study | Population | Intervention | BMI | Primary endpoint |
|---|---|---|---|---|
Breast cancer | ||||
DIANA-5170 | Early stage BC | Diet + exercise | All | Recurrence |
PREDICOP (NCT02035631) | Early stage BC | Diet + supervised exercise | 18–40 | Time to recurrence |
BWEL (NCT02750826) | Her2-negative early stage BC | Diet + PA | ≥27 | Invasive DFS |
DEDiCa (NCT02786875) | Early stage BC | Diet | All | DFS |
DIRECT (NCT02126449) | Stage II/II Her2-negative BC | Diet | ≥19 | Toxicity |
Efficacy of Dietary Fat Reduction (NCT00002564) | Stage I/II/IIIA BC | Diet | All | DFS, OS |
OPTITRAIN (NCT02522260) | Early stage BC | Exercise | All | Cancer-related fatigue |
EXCAP (NCT00851812) | Early stage BC | Exercise | All | Cancer-related fatigue |
Colon cancer | ||||
CHALLENGE187 | Stage II/III CRC | Exercise | All | DFS |
Prostate cancer | ||||
INTERVAL (NCT02730338) | MCRPC | Exercise | All | OS |
Endometrial cancer | ||||
REWARD (NCT01870947) | Stage I EC | Exercise | ≥30.0 | Weight change |
Step into Wellness (NCT03367923) | Stage IA–IIIA EC | Exercise | 25–60 | Activity level |
Ovarian cancer | ||||
LIVES (NCT00719303) | Stage II–IV OC | Diet + PA | >20 | PFS |
